Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
7,208 | Dovepress* | 6,640+ | 1,252 | 7,892 | |
PubMed Central* | 568 | 194 | 762 | ||
Totals | 7,208 | 1,446 | 8,654 | ||
*Since 20 October 2016 |
View citations on PubMed Central and Google Scholar